text

News

content-image

GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer

Scientific Advisory Board member, Dr. Noriyuki Kasahara, appointed Chief Scientific Officer of GenVivo, to accelerate the...
Read More >

GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential...
Read More >

GenVivo Highlights GEN2 Phase 1 Data and GEN-1013 Preclinical Data at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and...
Read More >